Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Table 1

Patient and donor characteristics.

Criteria	Group 1 (non-GVHD)	Group 2 (GVHD)
Patients,	7	7
Recipient
Age at HSCT (median (range))	47 (30–58)	51 (36–64)
Gender, (female/male)	3/4	3/4
Diagnosis,
AML	1	3
ALL	2	0
CLL	1	0
MDS/MPD	3	2
Solid tumour	0	2
Donor
HLA-identical sibling,	7	7
Age at HSCT (median (range))	40 (31–67)	54 (43–68)
Conditioning regimen,
Cy + fTBI	2	0
Cy + Bu	2	4
Flu + Bu	2	1
Flu + Cy	0	2
Cy + fTBI + Flu	1	0
Antithymocyte treatment,
ATG	1	0
Campath	1	0
GVHD prophylaxis,
CsA + MTX	7	5
FK + RAPA	0	2
Graft source,
PBSCs	7	7
Cell dose, median (range)
Total nucleated cells (×10^8/kg)	8.6 (7.5–21.6)	14.8 (5.0–24.5)
CD34^+ cells (×10^6/kg)	8 (4.7–11)	9.1 (4.3–9.6)

AML, acute myeloid leukaemia; ALL, acute lymphoblastic leukaemia; ATG, anti-T-cell globulin; Bu, busulfan; CLL, chronic lymphocytic leukaemia; CsA, cyclosporine A; Cy, cyclophosphamide; FK, tacrolimus; Flu, fludarabine; fTBI, fractionated total body irradiation; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorders; MTX, methotrexate; , number; PBSC, peripheral blood stem cell; RAPA, sirolimus. Statistical analysis was done with the Mann–Whitney test and Fisher’s exact test.